Crossmark

Longer scans boost prediction and cut costs in brain-wide association studies

Crossref DOI link: https://doi.org/10.1038/s41586-025-09250-1

Published Online: 2025-07-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ooi, Leon Qi Rong https://orcid.org/0000-0002-3546-4580
Orban, Csaba

Zhang, Shaoshi https://orcid.org/0000-0002-6352-9150
Nichols, Thomas E. https://orcid.org/0000-0002-4516-5103
Tan, Trevor Wei Kiat

Kong, Ru https://orcid.org/0000-0001-7842-0329
Marek, Scott

Dosenbach, Nico U. F. https://orcid.org/0000-0002-6876-7078
Laumann, Timothy O. https://orcid.org/0000-0002-0428-427X
Gordon, Evan M. https://orcid.org/0000-0002-2276-5237
Yap, Kwong Hsia

Ji, Fang

Chong, Joanna Su Xian https://orcid.org/0009-0008-5077-5206
Chen, Christopher https://orcid.org/0000-0002-1047-9225
An, Lijun https://orcid.org/0000-0003-1030-4625
Franzmeier, Nicolai

Roemer-Cassiano, Sebastian N. https://orcid.org/0000-0003-3423-457X
Hu, Qingyu https://orcid.org/0009-0007-5968-7854
Ren, Jianxun https://orcid.org/0000-0002-7885-4546
Liu, Hesheng https://orcid.org/0000-0002-7233-1509
Chopra, Sidhant

Cocuzza, Carrisa V.

Baker, Justin T.

Zhou, Juan Helen https://orcid.org/0000-0002-0180-8648
Bzdok, Danilo https://orcid.org/0000-0003-3466-6620
Eickhoff, Simon B.

Holmes, Avram J.

Yeo, B. T. Thomas https://orcid.org/0000-0002-0119-3276
,

Jack, Clifford R. Jr
License Information

Text and Data Mining valid from 2025-07-16

Version of Record valid from 2025-07-16
More Information

Article History

Received: 14 June 2023

Accepted: 5 June 2025

First Online: 16 July 2025

Competing interests

: D.B. is shareholder and advisory board member of MindState Design Labs. L.Q.R.O. and R.K. are co-founders of B1Neuro. B.T.T.Y. is a shareholder of B1Neuro. N.U.F.D. is a co-founder of Turing Medical. H.L. is a co-founder of Neural Galaxy. T.O.L. holds a patent for taskless mapping of brain activity licensed to Sora Neurosciences and a patent for optimizing targets for neuromodulation, implant localization and ablation. E.M.G. and N.U.F.D. may receive royalty income based on technology developed at Washington University School of Medicine and licensed to Turing Medical. T.O.L. and E.M.G. are consultants for Turing Medical. The content in this manuscript is unrelated to the activities of these companies.

Document is current

Any future updates will be listed below